DBV Technologies Enters Into Collaboration Agreement With Bionet-Asia And University of Geneva On Whooping Cough Booster Vaccine

Published: Nov 26, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PARIS, BANGKOK, Thailand and GENEVA, Nov. 26, 2013 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext Paris:DBV), creator of ViaskinĀ®, announced today that it has entered into a collaboration agreement with BioNet-Asia Co. Ltd and the University of Geneva (UNIGE) to work on a whooping cough (pertussis) booster vaccine. The clinical proof of concept product candidate will combine BioNet's unique recombinant non-toxic Pertussis Toxin (rPT) with DBV's ViaskinĀ® technology, which allows for the epicutaneous delivery of the antigen without any adjuvant.

Help employers find you! Check out all the jobs and post your resume.

Back to news